Dr Reddy’s Slides Against Market Rally Assemaglutide Concerns Weigh on Stock

Mumbai, April 15: Shares of Dr. Reddy’s Laboratories came under pressure in an otherwise firm market, slipping 1.5% at Rs 1,217.60even as benchmark indices traded higher, as concerns around its key growth driver — semaglutide — and a cautious brokerage outlook weighed on sentiment.

The stock declined after global brokerage Citi stated a bearish stance. The concerns stem largely from challenges in scaling up semaglutide — a blockbuster diabetes and weight-loss drug — particularly in markets such as Brazil, where regulatory and competitive dynamics remain uncertain. For one thing, Brazil’s regulator has denied the registration of semaglutide as the filing did not meet all technical requirements. Moreover, Dr Reddy’s is also awaiting final approval for semaglutide in Canada.

Citi has also highlighted the risk of overly optimistic market expectations around the drug’s potential, pointing to intensifying competition and execution challenges. The brokerage has maintained a ‘sell’ rating, warning of potential downside from current levels.

Persistent Overhang from Semaglutide

The semaglutide opportunity has been a key pillar of Dr Reddy’s growth narrative, but recent developments suggest the path may be more complicated than initially expected. Regulatory hurdles and increasing competition from global players have raised doubts about the scale and timing of potential revenues.

This is not the first time the stock has reacted negatively to such concerns. Back in October 2025, shares had dropped after a regulatory setback in Canada related to its semaglutide filing, underscoring the market’s sensitivity to developments around this molecule.

A Choppy Stock Journey

Over a longer period, the stock’s performance reflects a volatile trajectory shaped by both optimism and setbacks.

Dr Reddy’s shares have traded within a wide band over the past year, touching Rs 1,379.70 while also slipping to Rs 1,129 during regulatory or growth-related concerns.

While the stock has delivered around five per cent gains over a 12-month period, it has seen intermittent corrections, with sentiment frequently tied to developments in its speciality drug pipeline and pricing pressures in key markets. This year so far the stock is down around three per cent.

Why the Stock is Lagging Now

The current underperformance stands out particularly because it comes at a time when the broader market is witnessing a risk-on rally, driven by easing crude prices and improving global cues.

Analysts say the divergence reflects stock-specific concerns rather than sectoral weakness. Apart from semaglutide-related risks, the company is also facing:

• Pressure from declining contribution of key drugs such as Revlimid
• Lower incentives and margin headwinds
• Uncertainty around future growth drivers

Together, these factors have led investors to adopt a cautious stance, even as other sectors participate in the market rally.

Outlook: Growth vs Execution

Going ahead, the stock’s trajectory is likely to hinge on clarity around its speciality pipeline, particularly semaglutide, and the company’s ability to navigate regulatory and competitive challenges.

While Dr Reddy’s continues to have a strong base business and global presence, the near-term narrative appears to be dominated by execution risks and tempered growth expectations.

For now, the market seems to be sending a clear signal: in a rising market, stocks without clear visibility on growth catalysts risk being left behind — and Dr Reddy’s is currently in that camp.

Source: NSE